Our RiboFlux™ machine, has been selected as one of the four projects that will be funded under the PharmaNL Shared Development Infrastructure 2025 call. The 4 funded projects will aim on building and/or upgrading infrastructure for the development, upscaling and production of innovative medicines in the Netherlands. PharmaNL is one of the projects from the Dutch National Growth Fund and helps to fill in essential prerequisites for successful medicine innovations.
Our intent with RiboFlux™ is to take away the hurdles when it comes to the development of mRNA-based medicines and subsequent scaling of production to answer for instance the need for pandemic preparedness or personalized medicines.
It is designed to be the world’s first integrated, continuous-flow mRNA manufacturing system, to allow for drug developers to move seamlessly from research to GMP-scale production.
The highly automated and fully integrated machines make producing RNA-in-a-day™ a reality. From DNA amplification, DNA qualification, RNA synthesis, RNA purification and LNP formulation, all in one single workflow. And to top it off, this system will be developed to include automated quality control, to remove the high cost and waiting time.
By combining, speed – scalability – cost efficiency, drug developers will be in a position to rapidly iterate and advance candidates to the clinic faster and ultimately bring new therapies to patients.
Many thanks to PharmaNL and ZonMw and to everyone involved within RiboPro in making our vision a reality.
